Literature DB >> 33618740

m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.

Dan Jin1, Jiwei Guo2, Yan Wu3, Jing Du3, Lijuan Yang3, Xiaohong Wang4, Weihua Di5, Baoguang Hu6, Jiajia An7, Lingqun Kong8, Lei Pan9, Guoming Su10.   

Abstract

Entities:  

Year:  2021        PMID： 33618740      PMCID： PMC7901070          DOI： 10.1186/s13045-021-01048-8

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN： 1756-8722            Impact factor:   17.388


× No keyword cloud information.
  9 in total

Review 1.  The Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis.

Authors:  Xia Wu; Wu Ye; Yuping Gong
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

2.  Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma.

Authors:  Lele Ye; Kan Pan; Su Fang; Su-Ni Wu; Su Chen; Sangsang Tang; Nan Wang; Haoke Zhang; Xinya Tong; Xinyu Shi; Shiyu Feng; Dan Xiang; Ruanmin Zou; Yingying Hu; Xiangyang Xue; Gangqiang Guo
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 3.  Novel insights into the m6A-RNA methyltransferase METTL3 in cancer.

Authors:  Yiqing Cai; Rui Feng; Tiange Lu; Xiaomin Chen; Xiangxiang Zhou; Xin Wang
Journal:  Biomark Res       Date:  2021-04-20

Review 4.  Insights into N6-methyladenosine and programmed cell death in cancer.

Authors:  Li Liu; Hui Li; Dingyu Hu; Yanyan Wang; Wenjun Shao; Jing Zhong; Shudong Yang; Jing Liu; Ji Zhang
Journal:  Mol Cancer       Date:  2022-01-28       Impact factor: 27.401

5.  Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit-induced long intergenic non-protein coding RNA 1833 N6-methyladenosine methylation promotes the non-small cell lung cancer progression via regulating heterogeneous nuclear ribonucleoprotein A2/B1 expression.

Authors:  Dongliang Li; Zejun Fu; Chaoqun Dong; Yongming Song
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

6.  PLAA suppresses ovarian cancer metastasis via METTL3-mediated m6A modification of TRPC3 mRNA.

Authors:  Zhangjin Shen; Lingkai Gu; Yuwan Liu; Lingfang Wang; Jiawei Zhu; Sangsang Tang; Xinyi Wei; Jiaying Wang; Songfa Zhang; Xinyu Wang; Xiaodong Cheng; Xing Xie; Weiguo Lu
Journal:  Oncogene       Date:  2022-07-22       Impact factor: 8.756

Review 7.  Implications of m6A methylation and microbiota interaction in non-small cell lung cancer: From basics to therapeutics.

Authors:  Fen-Sheng Qiu; Jia-Qi He; Yu-Sen Zhong; Mei-Ying Guo; Chen-Huan Yu
Journal:  Front Cell Infect Microbiol       Date:  2022-09-02       Impact factor: 6.073

Review 8.  The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development.

Authors:  Shougeng Liu; Sihong Chen; Chengfang Tang; Yingxi Zhao; Wei Cui; Lina Jia; Lihui Wang
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

9.  Interplay of m6 A and histone modifications contributes to temozolomide resistance in glioblastoma.

Authors:  Fuxi Li; Siyun Chen; Jiaming Yu; Zhuoxing Gao; Zhangyi Sun; Yang Yi; Teng Long; Chuanxia Zhang; Yuzhe Li; Yimin Pan; Chaoying Qin; Wenyong Long; Qing Liu; Wei Zhao
Journal:  Clin Transl Med       Date:  2021-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.